Vegfd modulates both angiogenesis and lymphangiogenesis during zebrafish embryonic development by Bower, Neil I. et al.
RESEARCH ARTICLE
Vegfd modulates both angiogenesis and lymphangiogenesis
during zebrafish embryonic development
Neil I. Bower1, Adam J. Vogrin2, Ludovic Le Guen1, Huijun Chen1, Steven A. Stacker2,3, Marc G. Achen2,3 and
Benjamin M. Hogan1,*
ABSTRACT
Vascular endothelial growth factors (VEGFs) control angiogenesis
and lymphangiogenesis during development and in pathological
conditions. In the zebrafish trunk, Vegfa controls the formation of
intersegmental arteries by primary angiogenesis and Vegfc is
essential for secondary angiogenesis, giving rise to veins and
lymphatics. Vegfd has been largely thought of as dispensable for
vascular development in vertebrates. Here, we generated a zebrafish
vegfd mutant by genome editing. vegfd mutants display significant
defects in facial lymphangiogenesis independent of vegfc function.
Strikingly, we find that vegfc and vegfd cooperatively control
lymphangiogenesis throughout the embryo, including during the
formation of the trunk lymphatic vasculature. Interestingly, we find that
vegfd and vegfc also redundantly drive artery hyperbranching
phenotypes observed upon depletion of Flt1 or Dll4. Epistasis and
biochemical binding assays suggest that, during primary
angiogenesis, Vegfd influences these phenotypes through Kdr
(Vegfr2) rather than Flt4 (Vegfr3). These data demonstrate that,
rather than being dispensable during development, Vegfd plays
context-specific indispensable and also compensatory roles during
both blood vessel angiogenesis and lymphangiogenesis.
KEY WORDS: Vegfd, Vegfc, Flt4, Kdr, Lymphatic,
Lymphangiogenesis
INTRODUCTION
Signaling through the VEGF/VEGFR pathway is essential for
multiple steps during development of the vasculature. In zebrafish,
primary angiogenesis occurs when arterial sprouts emerge from the
dorsal aorta (DA) from ∼22 hpf to give rise to the intersegmental
arteries (aISV) in a process dependent on Kdr, Kdrl and Vegfa
(Bahary et al., 2007; Covassin et al., 2006; Lawson et al., 2002;
Lawson and Weinstein, 2002; Nasevicius et al., 2000; Olsson et al.,
2006). During primary angiogenesis, blood vessel sprouting is led
by tip cells, which express high levels of Flt4 (Vegfr3 in mammals)
and display active Erk signaling (Gore et al., 2011; Shin et al.,
2016a). In zebrafish, whole-genome duplication has resulted in the
presence of two Vegfr2 paralogs, Kdr and Kdrl (Bussmann et al.,
2008; Covassin et al., 2006). Tip cells are highly responsive to Kdr,
Kdrl and Flt4 signaling, and have low Notch-signaling activity. In
the zebrafish, the loss of Dll4, a Notch ligand, leads to increased
angiogenic sprouting (Leslie et al., 2007; Siekmann and Lawson,
2007). Dll4 negatively regulates arterial Flt4 signaling and
suppresses the arterial response to Vegfc (Hogan et al., 2009b;
Villefranc et al., 2013). Likewise, Flt1 (Vegfr1) also plays a
negative regulatory role, its soluble form (sFlt1) suppresses arterial
Vegfr signaling and angiogenesis, with morpholino (MO)
knockdown of Flt1 leading to aISV hyperbranching (Krueger
et al., 2011). Although Vegfa plays the dominant role in controlling
arterial sprouting and Vegfc has been shown to influence this
process, Vegfd has not previously been implicated in the regulation
of primary sprouts (Hogan et al., 2009b; Jakobsson et al., 2010;
Siekmann and Lawson, 2007).
The sprouting of both venous intersegmental vessels (vISV) and
lymphatic endothelial cells (LECs) occurs by secondary
angiogenesis from ∼32 hpf in zebrafish (Isogai et al., 2003).
Sprouts emerging from the cardinal vein can become vISVs or
LECs when they either anastomose with existing aISVs to form
vISVs, or fail to anastomose and migrate dorsally to form
parachordal LECs at the horizontal myoseptum (HM) (Isogai
et al., 2003; Koltowska et al., 2013, 2015). Parachordal LECs in the
HM proliferate and migrate dorsally and ventrally to form the major
trunk lymphatics: the thoracic duct (TD), dorsal longitudinal
lymphatic vessel (DLLV) and the intersegmental lymphatic vessels
(ISLVs) (Cha et al., 2012; Hogan et al., 2009b; Küchler et al., 2006;
Yaniv et al., 2006). Facial lymphangiogenesis proceeds from the
common cardinal vein (CCV) as lymphatic sprouts migrate to form
the lateral facial lymphatic (LFL), medial facial lymphatic (MFL)
and the otolithic lymphatic vessel (OLV) by 5 dpf (Okuda et al.,
2012). The formation of zebrafish lymphatic vessels is dependent on
the Ccbe1/Vegfc/Flt4 signaling axis (Hogan et al., 2009a; Le Guen
et al., 2014; Villefranc et al., 2013). Vegfd has been shown by MO
knockdown to compensate for loss of Vegfc during facial lymphatic
development but not elsewhere in the embryo (Astin et al., 2014).
Growth factor-induced signaling downstream of Flt4 occurs through
the activation of Erk, which is necessary and sufficient in the trunk
to induce the normal sprouting of LECs and expression of the LEC
marker Prox1 (Koltowska et al., 2015; Shin et al., 2016b). During
facial lymphangiogenesis from the CCV, Erk signaling controls
LEC sprouting but not Prox1 expression, suggesting spatially
distinct mechanisms that remain to be fully understood (Shin et al.,
2016b).
VEGFD is structurally related to VEGFC and can signal through
both VEGFR3 and VEGFR2 in humans but only through Vegfr3
in mice (Achen et al., 1998; Baldwin et al., 2001a). Overexpression
of VEGFD in tumor cells induces tumor angiogenesis,
lymphangiogenesis and the dilation of collecting lymphatic
vessels, ultimately promoting the metastatic spread of tumor cells
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et al., 2005). Expression of VEGFD in solid human tumors is a
strong indicator of metastasis and poor prognosis (Achen et al.,
2005; Stacker et al., 2014). However, despite this potent capability
of VEGFD, its function during embryonic development has
remained unclear. Vegfd knockout mice on a mixed genetic
background are viable with no obvious defects in blood or
lymphatic endothelium (Baldwin et al., 2005). Vegfc, Vegfd
double-knockout mice display a developmental phenotype that
appears to be the same as that of Vegfc knockout mice (Haiko et al.,
2008), hence it is considered that Vegfd is not involved during
embryonic development. However, postnatal phenotypes have been
observed in some tissues and include a reduction in the abundance
of pulmonary lymphatics (Baldwin et al., 2005) and, in adult mice
of a pure C57BL/6 background, smaller initial dermal lymphatics
and compromised function (Paquet-Fifield et al., 2013).
We have recently found that vegfd is expressed throughout the
embryonic trunk during zebrafish development (Duong et al.,
2014), suggesting a potential function that remains to be fully
explored. Here, we report the generation of a zebrafish vegfdmutant.
vegfd is dispensable for development of trunk blood and lymphatic
vessels. However, we find that vegfd is essential for normal facial
lymphangiogenesis and combines with vegfc contextually during
lymphangiogenesis throughout the trunk and face. Furthermore,
Vegfc and Vegfd together influence aISV development in a number
of knockdown or overexpression settings. In this context, Vegfd is
likely to act through Kdr, which we find binds to Vegfd in zebrafish.
These findings identify Vegfd as a developmental regulator of both
lymphangiogenesis and angiogenesis.
RESULTS
Generation of a zebrafish vegfdmutant
To investigate the developmental role of Vegfd, we used TALEN
mutagenesis to generate a zebrafish mutant harboring a 7 bp
deletion at base 162 of the vegfd-coding sequence. The deletion site
is in an exon common to both of the known protein-coding
transcript variants that contain the Vegfd homology domain (VHD).
The 7 bp deletion introduces a stop codon at amino acid 65, which is
prior to the VHD of the Vegfd protein and is predicted to result in a
null mutant (Fig. 1A,B). Analysis of the number of aISVs, vISVs
and the extent of the TD in the trunks of vegfduq9bh mutant embryos
revealed no differences between homozygous mutant, heterozygous
or wild-type embryos (Fig. 1C,D, Fig. S1A,B). vegfduq9bh
homozygous mutant embryos were raised to adulthood and
produced viable offspring (Fig. 1E-H). Analysis of vegfd mRNA
levels in embryos derived from in-crosses of vegfd homozygous
mutant adults showed that these mutant embryos had less than 50%
of the transcript levels of stage-matched wild-type embryos,
indicative of nonsense-mediated decay (NMD) (Fig. S1C).
Additionally, we did not observe any change in vegfc mRNA
levels in vegfduq9bh homozygous mutants, indicating that
compensation for the loss of vegfd is unlikely to occur (Fig. S1C).
Vegfd morpholino (MO) knockdown has previously been
reported and revealed that Vegfd compensates for the loss of
facial lymphatics in vegfchu5055 mutants (Astin et al., 2014). We
performed the reciprocal experiment, injecting a vegfc MO into
embryos produced from a cross of homozygous with heterozygous
vegfduq9bh mutants. Using an approach blinded for genotype, we
scored injected embryos as displaying ‘severe’ (defined as a
complete loss of the MFL and LFL) or ‘partial’ (indicating reduced
length of the MFL and LFL) phenotypes and found vegfduq9bh
mutants were enriched in the ‘severe loss’ category of embryos,
confirming previous findings and suggesting that these mutants did
not express functional Vegfd (Fig. S1D,E). Taking into account this
phenocopy of the MO-induced defects, the nature of the mutation
and detection of NMD, we suggest that the vegfduq9bh allele is a loss-
of-function allele and likely to be null.
Vegfd regulates lymphangiogenesis of the facial lymphatic
network
To more accurately characterize the role of Vegfd during
development of the facial lymphatics, we generated vegfduq9bh,
vegfchu5055 double mutants in a Tg(fli1a:negfp), Tg(-5.2lyve1b:
dsRed) transgenic background. This previously reported vegfchu5055
mutant is hypomorphic and displays a strong but variable loss of
lymphatics (Le Guen et al., 2014). The number of individual nuclei
in each of the different facial lymphatic vessels was quantified in
embryos from vegfduq9bh, vegfchu5055 double heterozygous in-
crosses (Fig. 1J-Q). In double mutant embryos, the facial lymphatics
failed to develop (Fig. 1N). Strikingly, vegfduq9bh mutant embryos
displayed fewer facial lymphatic nuclei in the LFL and MFL than in
wild-type embryos, without any reduction in vegfc gene dose
(Fig. 1L,O,P). There were also significantly fewer nuclei in
vegfchu5055, vegfduq9bh double heterozygotes compared with wild-
type embryos for both the LFL and MFL (Fig. 1K,O,P). Vegfd did
not contribute to the formation of the otolithic lymphatic vessel
(OLV), which was vegfc dependent (Fig. 1Q). Together, these data
show that vegfd regulates development of the facial lymphatics,
specifically the MFL and LFL, and that combined gene dose for
vegfc and vegfd is essential for the formation of the complete facial
lymphatic network.
Vegfd contributes to formation of the trunk lymphatic
vessels
vegfduq9bh mutant embryos develop normal trunk lymphatics in a
vegfc wild-type background (Fig. 1D, Fig. S1A). To determine
whether vegfd works together with vegfc in this context, we
examined the formation of parachordal LECs in the vegfchu5055
hypomorphicmutant in a vegfduq9bhmutant background (Fig. 2A-F).
In siblings that were homozygouswild type for the vegfchu5055 allele,
the loss of a single copy or both copies of vegfd did not produce any
lymphatic phenotype, indicating that Vegfd is dispensable for
normal trunk lymphangiogenesis in the presence of wild-type levels
of Vegfc (Fig. 2A,D). However, in a vegfchu5055 heterozygous
background, vegfduq9bh homozygous and heterozygous mutants
developed significantly fewer parachordal LECs than vegfduq9bh
wild-type embryos, demonstrating a compensatory role for Vegfd
with reduced gene dose for vegfc (Fig. 2E). Analysis of vegfduq9bh
allelic loss in a vegfchu5055 homozygous mutant background did not
reveal further significant interactions (Fig. 2F).
We next scored the extent of the TD across nine somites at 5 dpf. In
siblings that were homozygouswild type for the vegfchu5055 allele, the
loss of a single or both copies of vegfd again did not produce a
lymphatic phenotype (Fig. 3A,B). In both vegfchu5055 heterozygous
and homozygous mutant backgrounds, vegfduq9bh homozygous loss
led to significantly reduced TD extent (Fig. 3C-F,H,I). To more
accurately quantify the loss of TD in vegfduq9bh, vegfchu5055 double
mutant backgrounds,we precisely scored the numberof nuclei present
in the TD across 9 somites using the Tg(fli1a:negfp), Tg(-5.2lyve1b:
dsRed) transgenic strain (Fig. 3J-L). We found that many
hypomorphic vegfchu5055 homozygous mutant embryos partially
formed a TD; however, this was significantly reduced in the absence
of vegfd (Fig. 3J-L). In the majority of cases, double mutants failed to
form a single LEC in the region of the embryonic TD. Together, these
data show a compensatory role for vegfd with vegfc during trunk
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lymphangiogenesis, although vegfc alone is sufficient to generate a
trunk lymphatic vasculature during development.
Given the known and suggested biochemical interactions
between Flt4, Ccbe1 and Vegfd in zebrafish and in mammals, we
next examined whether there were genetic interactions between
mutants for these components during the formation of the TD. We
analyzed TD formation in embryos from vegfduq9bh, flt4hu4602 and
vegfduq9bh, ccbe1hu3613 double heterozygous in-crosses at 7 dpf.
ccbe1hu3613 homozygous mutant embryos had a complete loss of the
TD irrespective of vegfduq9bh genotypic status and wewere unable to
detect any genetic interaction in these crosses (data not shown).
Analysis of TD formation in embryos from vegfduq9bh, flt4hu4602
double heterozygous in-crosses revealed that, in a flt4hu4602
heterozygous background, vegfduq9bh mutants had significantly
reduced TD formation compared with vegfduq9bh heterozygous or
wild-type embryos (Fig. 3M-O). Hence, the flt4hu4602 mutation
dominantly interacts with the vegfduq9bh mutation, which does not
normally result in a TD phenotype.
Fig. 1. vegfd regulates facial lymphangiogenesis. (A) Forward (red) and reverse (blue) Talens used to target the vegfd locus induced a 7 bp deletion
designated as the uq9bh allele. (B) The uq9bh allele results in a premature stop codon at amino acid 65, prior to the VEGF homology domain. (C,D) Confocal
images of Tg(-5.2lyve1b:dsRed);Tg(flt1:yfp) wild-type (C, lyve1b:dsRed only; C′) and vegfduq9bh mutant embryos (D, lyve1b:dsRed only; D′) at 5 dpf.
(E-H) vegfduq9bh adult mutants are viable and have no obvious defects (G,H) when comparedwith siblings (E,F). (J-N′) Confocal images showing the facial region
of 5 dpf Tg(fli1a:negfp);Tg(-5.2lyve1b:dsRed) transgenic embryos produced by in-crossing vegfduq9bh, vegfchu5055 double heterozygotes. Arrows indicate the
presence of normal medial facial lymphatics (MFL), lateral facial lymphatics (LFL) and otolithic lymphatic vessel (OLV). Asterisks indicate the reduction of LEC
number in these vessels. (O-Q) vegfduq9bhmutant embryos have a reduced number of facial lymphatic endothelial cells (LECs) when quantified in 5 dpf Tg(fli1a:
negfp):Tg(-5.2lyve1b:dsRed) embryos. (O) Significant differences in LFL LEC numbers were observed when vegfduq9bh mutants (n=5) were compared with
vegfduq9bh heterozygous (n=12) or wild-type (n=7) embryos in a vegfchu5055 wild-type background; and when vegfduq9bh mutants (n=7) were compared with
vegfduq9bh heterozygous (n=18) or wild-type (n=6) embryos in vegfchu5055 mutants. (P) Significant differences in MFL LEC numbers were observed when
comparing vegfduq9bhmutants (n=6) with vegfduq9bhwild-type (n=7) embryos in a vegfchu5055wild-type background; when comparing vegfduq9bhmutant (n=10) or
heterozygous embryos (n=18) with vegfduq9bh wild type (n=6) and embryos in a vegfchu5055 heterozygous background; and when vegfduq9bhmutants (n=9) were
compared with vegfduq9bh heterozygous (n=18) andwild-type (n=6) embryos in a vegfchu5055mutant background. (Q) Therewas no interaction between vegfc and
vegfd in the formation of the otolithic lymphatic vessel. Data represent mean±s.e.m.; ***P<0.001, ** P<0.01, *P<0.05 from one-way ANOVA from three
independent clutches of embryos.
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Arterial defects induced by Vegfd overexpression are Kdr
(Vegfr2) dependent
VEGFC and VEGFD are capable of signaling through VEGFR3
(Flt4 in zebrafish) or VEGFR2 (Kdr and Kdrl in zebrafish) in
different settings (Achen et al., 1998; Covassin et al., 2006; Hogan
et al., 2009b; Joukov et al., 1996; Karnezis et al., 2012; Le Guen
et al., 2014; Villefranc et al., 2013). Overexpression of vegfd or
vegfc by mRNA injection in zebrafish causes bilateral turning of the
aISVs at 28-32 hpf (Astin et al., 2014; Hogan et al., 2009b). We co-
injected vegfd mRNA with a flt4 MO and found no decrease in the
number of turned aISVs when compared with vegfd mRNA
injection alone (Fig. 4B,F,I), whereas co-injection of flt4
morpholino with vegfc mRNA led to a rescue of the vegfc
mRNA-driven phenotype, as previously reported (Hogan et al.,
2009b) (Fig. S2A,B). To determine which receptor Vegfd is likely
signaling through, we co-injected vegfd mRNA with morpholinos
targeting other Vegf receptors. Importantly, we ensured that each of
these MOs was efficacious by using previously published MOs and
reproducing previously validated phenotypes. Specifically for the
MOs used in this study, ISV hyperbranching is robustly induced
using the flt1 MO (Krueger et al., 2011) and the dll4 MO (Hogan
et al., 2009b; Siekmann and Lawson, 2007); the kdr and kdrl MO
combined robustly block ISV development (but neither alone
achieves this) (Covassin et al., 2006; Wiley et al., 2011); and the flt4
MO blocks the formation of lymphatic vessels in a highly
reproducible manner (Hogan et al., 2009b). Co-injection of the
flt1MOwith vegfdmRNA led to an increase in the number of turned
aISVs at 28-32 hpf compared with embryos injected with vegfd
mRNA alone (Fig. 4B,G,H,J). Flt1 is known to suppress Vegfa
signaling through Vegfr2 (Kdr or Kdrl in zebrafish) (Krueger et al.,
2011; Wiley et al., 2011), but enhancement of the hyperbranching
phenotype by vegfd overexpression is unexpected. Co-injection of
vegfd mRNAwith kdrMO rescued the bilateral turning of the aISV
phenotype at 28-32 hpf (Fig. 4B,C,I), whereas injection with kdrl
MO failed to rescue (data not shown). We also co-injected vegfc
mRNA with kdr MO and found no rescue of the vegfc-driven
phenotype (Fig. S2B). It has previously been reported that
overexpression of Vegfd leads to an upregulation of Vegfr2 in
rabbit blood vessels (Rissanen et al., 2003), which could contribute
to the ectopic turning of aISVs in this setting. To examine this, we
performed qPCR on 28 hpf vegfd mRNA-injected embryos and
controls; we found no significant changes in the expression of kdr,
kdrl, flt4, vegfaa, vegfab, dll4, flt1 or fli1a (Fig. 4K). Together, these
data suggest that in the context of zebrafish aISV development,
Vegfc and Vegfd are capable of acting through Flt4 and Kdr,
respectively.
Zebrafish Vegfd is proteolytically processed and binds Kdr
The genetic evidence presented above suggests that zebrafish Vegfd
influences primary angiogenesis via interaction with Kdr. To further
confirm this, we tested the capacity of zebrafish Vegfd to bind Kdr.
Comparison of zebrafish and human VEGFD revealed that the
zebrafish protein has a similar primary domain structure with N- and
C-terminal propeptides flanking a central VEGF homology domain
(VHD) (Fig. 5A). Previous studies with human (Stacker et al., 1999)
and mouse (Baldwin et al., 2001b) VEGFD demonstrated that the
N- and C-terminal propeptides can be proteolytically cleaved to
generate a mature form consisting of dimers of the VHD. The
mature form of human VEGFD has much higher affinity for human
VEGFR2 compared with the full-length form (Stacker et al., 1999);
furthermore, the proteolytic processing of VEGFD is important for
its activity in disease settings (Harris et al., 2011). We therefore
expressed a form of full-length zebrafish Vegfd tagged at the
N-terminus with the FLAG octapeptide, designated zVegfd-FULL-
N-FLAG, in transiently transfected human HEK293T cells to assess
whether it can be proteolytically processed. Western blot analysis of
conditioned media (CM) revealed the presence of bands at ∼47, 36
and 15 kDa (Fig. 5B, left panel), consistent with the expected sizes
of full-length Vegfd, of a partially processed form containing the
N-terminal propeptide and the VHD, and of a form consisting of
only the N-terminal propeptide, respectively. These findings
confirm that zebrafish Vegfd can be proteolytically processed, at
least when expressed in mammalian cells.
Given that zebrafish Vegfd can be processed, and that the mature
form of human VEGFD exhibits higher affinity for VEGFR2 than
other forms of the growth factor, we used a mature form of zebrafish
Fig. 2. Vegfd contributes to the development of parachordal lymphatic endothelial cells. (A-C) Confocal images at 54 hpf showing presence (arrows) or
absence (asterisks) of PL formation in representative Tg(fli1a:egfp) vegfchu5055, vegfduq9bh mutant embryos. (D-F) Quantification of PL formation in vegfduq9bh
mutant embryos in vegfchu5055wild-type (D), heterozygous (E) andmutant (F) backgrounds. Therewere significantly fewer PLs formed in vegfduq9bh homozygous
mutant (n=42) and heterozygous (n=112) embryoswhen comparedwith vegfduq9bhwild-type (n=63) embryos in a vegfchu5055 heterozygous background (E). Error
bars represent mean±s.e.m.; ***P<0.001 from one-way ANOVA from three independent clutches of embryos.
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Fig. 3. Vegfd contributes to thoracic duct development in the zebrafish trunk. (A-F) Confocal images of Tg(fli1a:egfp) at 5 dpf showing formation of the
TD (arrows) is normal in vegfduq9b mutants (A,B). The phenotype for the formation of the TD is variable in vegfchu5055 mutants, ranging from a complete loss (C)
to very mild loss (D). The formation of the TD is reduced (asterisk) in vegfchu5055 mutants that were heterozygous (E) or mutant (F) for vegfduq9bh.
(G-I) Quantification of TD extent across nine somites in vegfduq9bh mutant embryos in vegfchu5055 wild-type (G), heterozygous (H) and mutant (I) backgrounds.
Therewas significantly less TD formed in vegfduq9bhmutant embryos (n=42) when comparedwith vegfduq9bh heterozygous (n=112) andwild-type (n=63) embryos
in a vegfchu5055 heterozygous background (H); and in vegfduq9bh mutant embryos (n=25) when compared with vegfduq9bh heterozygous (n=56) and wild-type
(n=33) embryos in a vegfchu5055 homozygous mutant background (I). Data represent mean±s.e.m.; *P<0.05 from Kruskal–Wallis test from three independent
clutches of embryos. (J-K′) Confocal images of TD formation in 5 dpf Tg(fli1a:negfp),Tg(-5.2lyve1b:dsRed) embryos showing that fragments of TD form in
vegfchu5055mutant/vegfduq9bhwild-type embryos (J,J′), but are absent in vegfchu5055 /vegfduq9bh double-mutant embryos (K,K′). (L) Quantification of experiment in
J-K′. The number of nuclei present in the TD of vegfduq9bh mutant (n=14) embryos was significantly lower when compared with vegfduq9bh heterozygous (n=21)
and vegfduq9bh wild-type (n=13) embryos in a vegfchu5055 mutant background. Data represent mean±s.e.m.; **P<0.01, from one-way ANOVA from three
independent clutches of embryos. (M,N) Confocal images of TD formation in 7 dpf Tg(-5.2lyve1b:dsRed) embryos (yellow arrows) in a flt4hu4602 heterozygous
background. vegfduq9bhmutants (N) have reduced TD formation compared with vegfduq9bhwild-type embryos (M). (O) Quantification of experiment in M,N. There
was significantly less TD formed in vegfduq9bh mutant embryos (n=33) when compared with vegfduq9bh heterozygous (n=19) and wild-type embryos (n=27) in a
flt4hu4602 heterozygous background. **P<0.01, *P<0.05 from Kruskal–Wallis test from three independent clutches of embryos.
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Vegfd, consisting of the VHD, for receptor-binding studies. A
version of mature zebrafish Vegfd tagged at the N-terminus with
FLAG, designated zVegfdΔNΔC-FLAG, was expressed in
transiently transfected HEK293T cells – the size of the subunits
of this glycoprotein was in the 21-28 kDa range (Fig. 5B, right
panel), as expected based on the sizes of mature human and mouse
Vegfd (Achen et al., 1998; Baldwin et al., 2001b). CM containing
zVegfdΔNΔC-FLAG were incubated with Ig-fusion proteins,
consisting of the extracellular domains of zebrafish Kdr or Kdrl
and the Fc region of mouse IgG, that were bound to protein A-
sepharose (seeMaterials andMethods). Western blotting of material
precipitated by the Ig-fusion proteins/protein A-sepharose revealed
that the Kdr extracellular domain could bind zVegfdΔNΔC-FLAG,
whereas the extracellular domain of Kdrl could not (Fig. 5C, left
panel). Hence, in line with our epistasis data above, mature Vegfd
can bind Kdr, but not Kdrl in zebrafish.
Vegfd is dispensable for early primary angiogenic sprouting
As our data suggest that Vegfd is capable of signaling through Kdr,
it is possible that vegfduq9bhmutants, upon loss of Kdrl, would show
arterial defects similar to the loss of Kdr and Kdrl together (Wiley
et al., 2011). To test this, we injected the kdrl MO into embryos
derived from a homozygous vegfduq9bh mutant crossed to a
heterozygous vegfduq9bh carrier. We independently quantified the
number of aISVs that extended fully from the DA to the DLAV and
the number of aISVs that had failed to sprout from the DA at 28 hpf
(Fig. S3A,B). We found no significant difference in the number of
aISVs between mutants or siblings upon Kdrl knockdown,
suggesting that Vegfa plays a dominant role in aISV sprouting
(Fig. S3A,B).
Given that vegfc mutants have been shown to interact genetically
with kdrl during primary angiogenesis (Villefranc et al., 2013), we
also examined the number of cells in the aISVs in vegfchu5055,
vegfduq9bh double mutants at 28 hpf using the Tg(fli1a:negfp)
transgenic background; however, we did not find any significant
difference (Fig. S3C). This implies that Vegfa plays a more potent
role than Vegfd. Although Vegfd is dispensable for early primary
angiogenic sprouting, the ability to signal through Kdr when
overexpressed shows that Vegfd is capable of inducing
angiogenesis, which may be important in pathological states or in
some mutant or knockdown settings.
Dll4 suppresses Vegfd signaling in developing
intersegmental arteries
In zebrafish, loss of the Notch ligand Dll4 leads to increased tip cells
and angiogenic sprouting because Dll4 negatively regulates Vegfc-
driven arterial Flt4 signaling (Hogan et al., 2009b; Siekmann and
Lawson, 2007; Villefranc et al., 2013). However, in vegfc mutants
injected with dll4 MO some arterial hyperbranching was still
observed, despite the vegfcum18 allele used being shown to be a null
allele (Villefranc et al., 2013).We injecteddll4MOinto embryos from
a vegfchu5055, vegfduq9bh double heterozygous incross and quantified
hyperbranching of aISVs followed by retrospective genotyping of the
embryos (Fig. 6A-E). Although there was no reduction in
Fig. 4. Vegfd mRNA injection induces artery defects in a Kdr-dependent manner. (A-F) Injection of vegfd RNA into Tg(fli1a:egfp) embryos causes
bilateral turning of aISVs (arrows) at 28-32 hpf (n=31, A,B), which is rescued by co-injection of a morpholino against kdr (C,D), but not flt4 morpholino injection
(E,F). (G,H) Co-injection of flt1 morpholino and vegfd RNA increases the bilateral turning of aISVs (n=20) when compared with vegfd RNA (n=31) or flt1
morpholino alone (n=29) (compare A,B,G and H). (I,J) Quantification of experiments presented in A-E (I) andG,H (J). Data represent mean±s.e.m.; ****P<0.0001,
***P<0.001 from one-way ANOVA. Data were obtained from three independent injections. (K) qPCR analysis of vegf receptor and ligand expression in uninjected
and vegfd mRNA-injected embryos shows no significant difference in mRNA levels for any of the genes examined.
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hyperbranching in vegfduq9bh mutants alone, there was a significant
reduction of hyperbranching in vegfduq9bh, vegfchu5055 doublemutants
compared with single vegfchu5055 mutants (Fig. 6C-E). This suggests
that Vegfc is sufficient to drive the phenotype, but Vegfd acts in a
compensatory manner. We conclude that Dll4 suppresses both Vegfc
and Vegfd signaling in developing intersegmental arteries.
Flt1 suppresses Vegfd and Vegfc signaling and interacts
with Dll4 in developing intersegmental arteries
Vegfr1 (Flt1 in zebrafish) plays a negative regulatory role during
angiogenesis, with its soluble form (sFlt1) suppressing arterial Vegfr
signaling and the knockdown of Flt1 leading to arterial
hyperbranching (Hiratsuka et al., 1998; Krueger et al., 2011).
Given the known interaction between Dll4/Notch signaling and Flt1
(Jakobsson et al., 2010), and our observation that Flt1 knockdown
enhances the vegfd mRNA injection phenotype (Fig. 4H), we
injected flt1 MO into embryos from a vegfchu5055, vegfduq9bh double
heterozygous in-cross. In a vegfchu5055 heterozygous background, we
found significantly fewer hyperbranched aISVs in vegfduq9bh
heterozygous and homozygous mutant embryos compared with
wild-type sibling embryos at 72 hpf (Fig. 6F-J). In a vegfchu5055
mutant background, there were also fewer hyperbranched aISVs in
Fig. 5. Zebrafish Vegfd is proteolytically processed
and binds Kdr. (A) Schematic map of the domain
structure of zebrafish Vegfd and of Vegfd derivatives
used in this study. In the domain map (top), SS denotes
signal sequence for protein secretion; N-pro and C-pro
denote N- and C-terminal propeptides, respectively;
VHD denotes the VEGF homology domain. Primary
translation products of zebrafish Vegfd derivatives
zVegf-d-FULL-N-FLAG and zVegf-dΔNΔC-FLAG are
depicted below but signal sequences are not shown. An
encircled F indicates the FLAG octapeptide tag; other
amino acids not present in zebrafish Vegfd are shown
using single-letter code. (B) Analysis of zebrafish Vegfd
expressed in human HEK293T cells. zVegf-d-FULL-N-
FLAG and zVegf-dΔNΔC-FLAG were transiently
expressed in HEK293T cells, and the resulting
conditioned media (CM) analyzed by western blotting to
detect the FLAG tag (zVegf-d-FULL-N-FLAG in the left
panel; zVegf-dΔNΔC-FLAG in the right panel). Control
indicates CM of cells transfected with expression vector
lacking Vegfd. Two different exposures for detection of
zVegf-d-FULL-N-FLAG are shown so that the FLAG tag
and N-pro bands can be clearly visualized. (C) Analysis
of the binding of mature zebrafish Vegfd to zebrafish Kdr
and Kdrl. zVegf-dΔNΔC-FLAG was precipitated from the
CM of transfected HEK293T cells using soluble Ig-fusion
proteins consisting of the extracellular domains of
zebrafish Kdr or Kdrl and the Fc region of mouse IgG, or
of the Fc region only (zKdr-Fc, zKdrl-Fc and Fc,
respectively), and detected by western blotting for the
FLAG tag under reducing conditions (left panel). Control
precipitations were performed from CM of cells
transfected with expression vector lackingDNA for Vegfd
(negative control, center panel). A western blot with
anti-mouse IgG was performed to detect the Fc regions
of Ig-fusion proteins used in precipitation reactions (right
panel). The positions of Fc, zKdr-Fc and zKdrl-Fc are
indicated (the expected sizes are ∼34, ∼150 and
∼150 kDa, respectively), and a dashed line indicates
where irrelevant tracks have been excised from the
image. The blot shows that similar levels of zKdr-Fc and
zKdrl-Fc were included in precipitations. The identity of
the band at ∼80 kDa in the Kdr-Fc track is unknown but it
may represent a proteolytically processed form of Kdr-
Fc. In B and C, schematic representations of detected
forms of zebrafish Vegfd, as inferred from previous
studies on human and mouse Vegfd (Baldwin et al.,
2001b; Stacker et al., 1999), are shown on the right
(F indicates FLAG tag).
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vegfduq9bh heterozygous and homozygous mutant embryos versus
wild-type siblings (Fig. 6J). We also found less hyperbranching of
aISVs when vegfchu5055 heterozygous and mutant embryos were
compared with wild-type siblings (Fig. S4A). These data indicates
that Flt1 inhibits Vegfc and Vegfd signaling during primary
angiogenesis, either directly or through its modulation of Vegfa
signaling.
To further examine this scenario, we generated a dll4 mutant
harboring a 2 bp deletion at base 90 of the dll4-coding sequence. This
deletion introduces a frame shift and a premature stop codon at amino
acid 47 (Fig. S4B). We found that at 5 dpf dll4uq10bh heterozygous
embryos displayedmild hyperbranching of the intersegmental arteries,
confirming dll4MO and hypomorphic mutant phenotypes (Fig. S4C)
(Leslie et al., 2007; Siekmann and Lawson, 2007). dll4 carriers had a
poor survival rate of 6.25% in the F2 population. Given that the aISV
hyperbranching in flt1 morphant embryos was reduced in the
vegfchu5055, vegfduq9bh double mutants, we injected the flt1 MO into
embryos from a dll4uq10bh+/− outcross and quantified the extent of
artery hyperbranching at 72 hpf. This is a time pointwhere the flt1MO
injection induces hyperbranching of aISVs, but dll4uq10bh
heterozygous mutants do not show hyperbranching (Fig. 6G,L). We
found that dll4uq10bh heterozygosity significantly enhanced the
hyperbranchingof aISVs induced by flt1MOknockdown (Fig. 6N,O).
Finally, following our observations that the bilateral turning of
arteries by vegfc and vegfd overexpression is Flt4 or Kdr dependent,
respectively, we co-injected kdr and flt1MOs, and also flt4 and flt1
Fig. 6. Dll4 and Flt1 suppress Vegfc and
Vegfd signaling in developing
intersegmental arteries. (A-D) Confocal
images of aISVs in 3 dpf Tg(fli1a:egfp)
uninjected wild-type control (A), dll4
morpholino (MO)-injected control (B), dll4
MO-injected vegfchu5055 mutant (C) and dll4
MO-injected vegfchu5055, vegfduq9bh double
mutant (D) embryos. Arrows indicate
hyperbranching. (E) Quantification of
hyperbranching in the experiment shown in
A-D. dll4 MO-injected vegfchu5055, vegfduq9bh
double-mutant embryos (n=20) had
significantly fewer hyperbranched aISVs than
dll4 MO-injected vegfchu5055 mutants (n=15).
(F-I) Confocal images of aISVs in 3 dpf
Tg(fli1a:egfp) uninjected wild-type control (F),
flt1 MO-injected control (G), flt1 MO-injected
vegfchu5055 mutant (H) and flt1 MO-injected
vegfchu5055, vegfduq9bh double-mutant
embryos (I). Arrows indicate hyperbranching.
(J) Quantification of hyperbranching in the
experiment shown in F-I. flt1 MO-injected
vegfchu5055, vegfduq9bh double-mutant
embryos (n=34) had significantly fewer
hyperbranched aISVs than vegfduq9bh
heterozygous (n=75) and wild-type (n=43)
embryos in a vegfchu5055 heterozygous
background. vegfduq9bh mutant embryos
(n=14) also had significantly fewer
hyperbranched aISVs than vegfduq9bh
heterozygous (n=52) and wild-type (n=23)
embryos in a vegfchu5055 mutant background.
(K-N) Confocal images of aISVs in uninjected
Tg(fli1a:egfp) wild-type embryos (n=21) (K),
uninjected dll4uq10bh heterozygous embryos
(n=22) (L), flt1 MO-injected wild-type
embryos (n=37) (M) and flt1 MO-injected
dll4uq10bh heterozygous embryos (n=29) (N)
at 3 dpf. Arrows indicate hyperbranching.
(O) Quantification of hyperbranching in the
experiment shown in K-N. There was no
hyperbranching of aISVs in dll4uq10b
heterozygous embryos compared with their
wild-type siblings at 3 dpf (the phenotype
initiates later in heterozygotes – see Fig.
S3C). Hyperbranching was induced by 3 dpf
following injection of flt1 MO in wild-type
embryos and the effect was significantly
enhanced in dll4uq10b heterozygous embryos.
For all of the above analysis, data are
mean±s.e.m.; ****P<0.0001, **P<0.01,
*P<0.05 from one-way ANOVA. Data were
obtained from three independent MO
injections.
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MOs and found a significant reduction in hyperbranching in each of
these separate co-injection scenarios compared with flt1 MO only
(Fig. S4D). Consistent with vegfc having the greatest impact on
hyperbranching in mutant analyses (Fig. 6J), Flt4 knockdown
produced the most significant reduction in this experiment
(Fig. S4D). These data, combined with the findings above further
demonstrate that flt1 genetically interacts with vegfc and vegfd.
DISCUSSION
A role for Vegfd in developmental angiogenesis and
lymphangiogenesis
Here, we describe a zebrafish vegfd mutant produced by Talen-
induced mutagenesis. The vegfduq9bh mutant is viable and displays
no obvious defects in primary or secondary angiogenesis in the
trunk. This mutant is most likely a null, based on the nature of the
mutation, an interaction with vegfc compared with published loss-
of-function data (Astin et al., 2014) and NMD of the vegfd
transcript. VEGFD has been widely considered to be dispensable
for developmental lymphangiogenesis based on studies in
knockout mice (Baldwin et al., 2005; Haiko et al., 2008).
However, phenotypes have been observed in postnatal settings
(Paquet-Fifield et al., 2013) and during pathological processes
(Stacker et al., 2001). Furthermore, Vegfd genetically interacts with
Sox18 during mouse blood vascular development (Duong et al.,
2014), suggesting its potential during embryonic development. Our
findings are made by high-resolution quantitative analysis of
lymphangiogenesis, including determining total LEC numbers per
vessel. These phenotypes demonstrate that Vegfd plays
compensatory roles with Vegfc in both the face and trunk, and
Vegfd alone is indispensable during facial lymphangiogenesis of
the LFL and MFL (see Fig. 7). These findings warrant further
detailed analysis of LEC number in different vessel beds in the
Vegfc, Vegfd double-knockout murine model. Of relevance to
human lymphatic disease, we show that vegfd gene dose broadly
modifies Vegfc/Flt4 pathway phenotypes in a variety of mutant
models and settings. Zebrafish with mutations in genes involved in
this pathway are disease models of heritable lymphedema (Alders
et al., 2009; Connell et al., 2010, 2009; Crawford et al., 2016;
Evans et al., 2003; Gordon et al., 2013; Hogan et al., 2009a,b;
Karkkainen et al., 2000; Shin et al., 2016b; Villefranc et al., 2013).
Given that ∼30% of cases of primary (inherited) lymphoedema are
caused by mutations in the Ccbe1/Vegfc/Vegfr3 (Flt4) pathway
(Mendola et al., 2013), it may be that Vegfd variants can modify
patient outcomes.
During primary angiogenesis in zebrafish, vegfc and vegfd are
expressed in the DA and the trunk, respectively (Duong et al., 2014;
Hogan et al., 2009b). Despite this, normal angiogenesis was
observed in vegfc, vegfd double mutants and is also seen in flt4-null
Fig. 7. Working model showing major contributors to Vegf signaling-mediated angiogenesis and lymphangiogenesis in zebrafish. Factors shown
in brackets play redundant or compensatory roles; factors not in brackets are indispensable. Vegfd can compensate for reduced but not absent Vegfc during
trunk lymphangiogenesis. However, during facial lymphangiogenesis Vegfd has an indispensable role in formation of the MFL and LFL but not the OLV. The
combined gene dose of vegfc and vegfd is essential for the development of the complete, normal facial lymphatic network. During primary angiogenesis, the
Flt1 knockdown phenotype (shown in the schematic) and Dll4 knockdown phenotype (not shown) are driven by Vegfc and Vegfd signaling, although Vegfc and
Vegfd are dispensable for normal artery development. DLAV, dorsal longitudinal anastomosing vessel; PL, parachordal LEC; DA, dorsal aorta; PCV, posterior
cardinal vein; DLLV, dorsal longitudinal lymphatic vessel; ISLV, intersegmental lymphatic vessel; TD, thoracic duct; aISV, arterial intersegmental vessel; vISV,
venous intersegmental vessel.
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mutants (Kok et al., 2015). Both Dll4 and Flt1 negatively regulate
arterial angiogenesis, with loss of either resulting in severe
hyperbranching of the aISVs (Krueger et al., 2011; Leslie et al.,
2007; Siekmann and Lawson, 2007). Here, we find that both Vegfc
and Vegfd contribute to these phenotypes (see Fig. 7). Interestingly,
although the aISV defects observed upon overexpression of vegfd
and vegfc are grossly similar, the ligands appear to act through
different mechanisms. The vegfc overexpression phenotype is
strongly enhanced in the absence of Dll4, whereas the vegfd
overexpression phenotype is only slightly enhanced (Hogan et al.,
2009b). Consistent with this, we found that the bilateral turning of
aISVs following injection of vegfc mRNA requires Flt4 and
following injection of vegfd mRNA requires Kdr. Overall, our data
suggest that zebrafish Vegfd can signal through Kdr (Vegfr2) during
primary angiogenesis and most likely through Flt4 during
secondary angiogenesis based on genetic interactions.
Interestingly, a recent study by Shin et al. shows that Prox1
induction in zebrafish facial lymphatics can occur in the absence of
Flt4 signaling (Shin et al., 2016b), but in the trunk the induction of
Prox1 expression is Vegfc/Flt4 dependent (Koltowska et al., 2015;
Shin et al., 2016b). These studies combined suggest that differential
signaling events are at play in facial and trunk lymphangiogenesis.
Perhaps, given our findings, further examination of Vegfd signaling
may help to illuminate these different mechanisms.
Our biochemical data show that Vegfd is capable of binding to
Kdr but not to Kdrl. Zebrafish Vegfd is capable of rescuing Vegfaa
zebrafish mutants (Rossi et al., 2016), which strongly supports our
data and together suggests that Vegfd can activate signaling
downstream of Kdr. As mouse Vegfd does not bind to Vegfr2 but
the human protein does (Baldwin et al., 2001a), zebrafish may
present a very useful alternative model for studying the function of
VEGFD/VEGFR2 signaling. Further to these binding studies, we
also show that full-length zebrafish Vegfd is processed by
proteolytic cleavage of the N- and C-terminal propeptides to
generate the mature Vegfd peptide. This resembles the processing of
mammalian/human VEGFD, via the proprotein convertases furin,
PC5 and PC7 (McColl et al., 2003, 2007), and the processing of
zebrafish Vegfc, which likely requires the proprotein convertases
furin, PC5 and PC7 (Khatib et al., 2010), similar to requirements in
mammalian systems (Joukov et al., 1996; Siegfried et al., 2003).
Activation of VEGFC requires CCBE1 and ADAMSTS3, but
VEGFD is not processed in a CCBE1-dependent manner in these
mammalian models (Bui et al., 2016; Jeltsch et al., 2014). By
contrast, in zebrafish-overexpression models it was shown that
Vegfd activity is Ccbe1 dependent (Astin et al., 2014). Uncovering
differences between species in VEGF processing, activation and
signaling may reveal novel and selective capabilities that can be
exploited therapeutically and further our fundamental understanding
of vascular development.
MATERIALS AND METHODS
Zebrafish
All zebrafish strains were maintained and animal work performed in
accordance with the guidelines of the animal ethics committee at The
University of Queensland, Australia. The previously published transgenic
and mutant lines are listed in Table S1.
TALEN genome editing
Talen monomers (Table S2) for vegfd and dll4 were generated using the
golden gate kit (Cermak et al., 2011), cloned into the pCS2TAL3RR and
pCS2TAL3DD backbones and transcribed as previously described
(Dahlem et al., 2012). Fish were screened by high resolution melt
analysis (HRMA) using a Viia7 Real-Time PCR System (Applied
Biosystems) and F1 embryos carrying a 7 bp deletion for vegfd and 2 bp
for dll4 were outcrossed to Tg(flt:YFP);Tg(-5.2lyve1b:dsRed) to generate
an F2 population. Primers for HRMA and sequencing of individual
mutations are listed in Table S2.
Injections, qPCR and genotyping
Capped RNA was transcribed and injected as previously described (Hogan
et al., 2009b). MOs used are listed in Table S3. DNA extraction from fin
clips and embryos was performed as previously described (Dahlem et al.,
2012). Primers for genotyping vegfd and vegfc mutants by KASP assays
(LGC Genomics) are listed in Table S2. dll4 mutants were genotyped by
EcoRI restriction digest of amplified PCR product (Table S2). Quantitative
real-time PCR was performed as previously described (Coxam et al., 2014)
using the primers indicated in Table S2.
Imaging
Zebrafish embryos were mounted in 0.5% low melting agarose and imaged
using a Zeiss LSM 710 FCS confocal microscope. Images were processed
using Image J 1.47 software (National Institutes of Health). The number of
nuclei expressing Tg(fli1a:negfp) and co-expressing Tg(-5.2lyve1b:dsRed)
in the TD or facial lymphatics were manually counted through a z-stack.
Nuclei in theMFL and LFLwere counted from the branch point of these two
vessels. Quantification of bilateral turning of aISVs at 28-32 hpf,
hyperbranching of aISVs at 3 dpf and PLs in 54 hpf, and TD in 5 dpf
embryos was performed by live scoring using a Leica M165FCmicroscope.
Expression vectors
The extracellular domains for Kdr (amino acids 23-773) and Kdrl (amino
acids 29-738) were PCR amplified and cloned using Infusion enzyme
(Clontech, CA, USA) into the pFUSE-mlgG2Aa-Fc2 (IL2ss) vector
(InvivoGen, CA, USA) using the primers listed in Table S2. Full-length
vegfd cDNA encoding both N- and C-terminal propeptides flanking the
Vegfd homology domain (VHD) (with the signal peptide amino acids 1-22
removed) and cDNA encoding the zebrafish Vegfd VHD (amino acids 85-
198) were PCR amplified using primers listed in Table S2. Products were
then cloned into pEFBOSSFLAG (Achen et al., 1998) immediately
downstream from the DNA sequence for the interleukin 3 signal sequence
using Infusion enzyme (Clontech, CA, USA) to generate zVegf-d-FULL-N-
FLAG and zVegf-dΔNΔC-FLAG, respectively. A threonine and an arginine
residue were included in the Vegfd constructs as artifacts from cloning, see
Fig. 5 for details.
Transient transfections and receptor binding assays
HEK293T cells were maintained in DMEM supplemented with 10%
FBS, 2 mM glutamax (Life Technologies Australia, Victoria, Australia),
100 U/ml penicillin and 100 µg/ml streptomycin (Life Technologies
Australia) at 37°C in a humidified atmosphere of 10% CO2.
HEK293T cells were transfected with expression vectors, as indicated,
using lipofectamine 2000 (Life Technologies Australia) according to the
manufacturer’s instructions. Briefly, cells in 5 ml of DMEM in 10 mm
tissue culture dishes were transfected with 10 µg of plasmid DNA and 40 µl
of lipofectamine 2000. Cells were then incubated for 6 h before addition of
5 ml of DMEM containing 0.4% BSA, and were then starved by further
incubation for 24 h. Conditioned media (CM) were collected and clarified
via centrifugation at 150 g for 5 min at room temperature. CM containing
Vegfd derivatives were used either directly for western blotting or in binding
studies with Ig-fusion proteins. For binding studies, Ig-fusion proteins were
precipitated from CMwith protein A-sepharose (Sigma Aldrich, MO, USA)
by incubation at 4°C for 3 h followed by centrifugation (1500 g for 5 min at
4°C). Ig-fusion proteins bound to protein A-sepharose were then incubated
with CM containing zebrafish Vegfd for 16 h at 4°C, and the sepharose was
then washed once with 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1%
Triton X-100, once with 500 mM NaCl and once with 50 mM Tris-HCl
(pH 8.0), before heating in reducing LDS sample buffer (Life Technologies
Australia) at 95°C for 5 min. Samples were then analyzed by SDS-PAGE/
western blotting using Bolt 4-12% Bis Tris plus gels (Invitrogen, CA, USA)
and proteins were transferred to iBlot2 nitrocellulose membrane (Invitrogen)
516
RESEARCH ARTICLE Development (2017) 144, 507-518 doi:10.1242/dev.146969
D
E
V
E
LO
P
M
E
N
T
using an iBlot2 protein transfer apparatus (Life Technologies, CA, USA).
Blots were probed with M2 anti-FLAG monoclonal antibody (catalogue
number F3165; Sigma-Aldrich) that had been conjugated to 800 IR dye (LI-
COR Biosciences, NE, USA) according to the dye manufacturer. Detection
was performed using an Odyssey Cx imaging system (LI-COR
Biosciences). Soluble Ig-fusion proteins used for binding studies were
shown to be of expected sizes by western blotting with goat anti-mouse IgG
antibodies (catalogue number 926-32210, LI-COR Biosciences).
Statistical analysis
Statistical analysis was performed using Prism software (GraphPad
software). When data conformed to parametric assumptions, ANOVA
using Fisher’s individual error post-hoc test was used to identify significant
differences. When parametric assumptions were not met, Kruskal–Wallis
test was used.
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Fastré, E., Bygum, A., van der Vleuten, C., Fagerberg, C., Baselga, E. et al.
(2013). Mutations in the VEGFR3 signaling pathway explain 36% of familial
lymphedema. Mol. Syndromol. 4, 257-266.
Nasevicius, A., Larson, J. and Ekker, S. C. (2000). Distinct requirements for
zebrafish angiogenesis revealed by a VEGF-A morphant. Yeast 17, 294-301.
Okuda, K. S., Astin, J. W., Misa, J. P., Flores, M. V., Crosier, K. E. and Crosier,
P. S. (2012). lyve1 expression reveals novel lymphatic vessels and new
mechanisms for lymphatic vessel development in zebrafish. Development 139,
2381-2391.
Olsson, A.-K., Dimberg, A., Kreuger, J. and Claesson-Welsh, L. (2006). VEGF
receptor signalling — in control of vascular function. Nat. Rev. Mol. Cell Biol. 7,
359-371.
Paquet-Fifield, S., Levy, S. M. Sato, T., Shayan, R., Karnezis, T., Davydova, N.,
Nowell, C. J., Roufail, S., Ma, G. Z.-M., Zhang, Y.-F., et al. (2013). Vascular
endothelial growth factor-d modulates caliber and function of initial lymphatics in
the dermis. J. Invest. Dermatol. 133, 2074-2084.
Rissanen, T. T., Markkanen, J. E., Gruchala, M., Heikura, T., Puranen, A.,
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